SciClone Pharmaceuticals (NASDAQ: SCLN) today announced abstract presentations of pre-clinical and clinical data from two separate studies evaluating the activity of ZADAXIN®, also known as thymosin alpha 1, against the hepatitis B virus (HBV). These abstracts were presented during the annual conference of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, California.
